1 / 5

Authors: Sunil Verma Date posted: September 28 th , 2009

SOLTI-0701, a randomized Phase IIb trial evaluating the efficacy and safety of sorafenib in combination with capecitabine for the treatment of patients with locally advanced or metastatic breast cancer Presented by Dr. Jose Baselga. Authors: Sunil Verma Date posted: September 28 th , 2009.

blade
Download Presentation

Authors: Sunil Verma Date posted: September 28 th , 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SOLTI-0701, a randomized Phase IIb trial evaluating the efficacy and safety of sorafenib in combination with capecitabine for the treatment of patients with locally advanced or metastatic breast cancerPresented by Dr. Jose Baselga Authors: Sunil Verma Date posted: September 28th, 2009

  2. Control arm: Capecitabine 1000mg/m2 bid (d1-14) + Placebo R Experimental arm: Capecitabine 1,000 mg/m2 bid + Sorafenib 400mg po bid N=229 MBC 1st or 2nd line Her 2 normal

  3. RESULTS

  4. STUDY COMMENTARY • Sorafenib is an oral multi-kinase inhibitor with anti-angiogenic and anti-tumor activity. It has documented activity and use in Hepatocellular and Renal Cell Cancer • This is a large well conducted randomized phase IIb placebo-controlled clinical trial • Efficacy results show a marked improvement in PFS which is particularly impressive for patients receivng this combination in first line MBC setting (7.6 m vs 4.1m) • Toxicity was concerning especially for Hand Foot Syndrome in combination arm where 45% of patients had grade3/4 HFS. • OS data in not yet mature and is expected in 2010

  5. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • RIBBON-1 Trial was the first trial that showed that capecitabine + anti-angiogenic agent (Bevacizumab) improves outcomes in MBC • This study confirms that anti-angiogenic approach in combination with capecitabine is effective even when combined with an oral multi-kinase inhibitor i.e. sorafenib • This is the second trial that shows that small molecules when combined with chemotherapy are efficacious. The previous trial evaluated lapatinib in combination with capecitabine for her2 positive patients • While there is significant improvement in PFS in this trial, there is considerable Grade ¾ HFS toxicity with this combination • It is exciting to have a new player in MBC in sorafenib, but more work needs to be done to evaluate predictive biomarkers, use with ideal chemo/targeted partners and addressing toxicity with this agent.

More Related